MARK SIRGO, PHARMD
Chief Executive Officer
Pharmaceutical executive and entrepreneur with over thirty 35 years of industry experience from large pharma to start-up. More recently founder and CEO of BioDelivery Sciences (Nasdaq:BDSI) that went from a preclinical stage start up to a fully integrated commercial enterprise following the FDA approval of three products ending in a successful sale of the company in 2022.
Prior to BDSI, held senior positions in research and development involving ethical and over-the-counter switch products in the areas of gastrointestinal, cardiovascular, respiratory, pain and addiction at GSK. In addition, led the management of global sales and marketing for a global contract research organization (PPD). Dr. Sirgo holds a Doctorate in Pharmacy from Philadelphia College of Pharmacy and BS in Pharmacy from The Ohio State University.
Mission
An innovative drug is one thing. An innovative delivery system that lets millions more benefit from it is another.
Heritage
A legacy of delivering firsts.
Technologies
Pioneering penetrating breakthroughs.
Manufacturing
Cutting-edge technologies demand cutting-edge production.
Partnerships
Game-changing delivery platforms lead to game-changing products.